Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes pill boost heart and muscle health in kidney patients?

NCT ID NCT07060417

Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This Phase 2 study will test whether empagliflozin (Jardiance), a drug already used for diabetes, can improve blood vessel health and exercise tolerance in 52 veterans with non-diabetic chronic kidney disease. Participants will take either the drug or a placebo for a period, and researchers will measure changes in artery function and leg blood flow. The goal is to see if this medication offers benefits beyond blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin (Jardiance)
What this could lead to
If successful, this could show that empagliflozin helps protect blood vessels and improve physical function in people with chronic kidney disease who do not have diabetes.
What could go wrong
This is a small, early-stage trial with only 52 participants, so results may not apply to everyone. It is also testing effects on blood vessel function rather than hard outcomes like kidney failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * eGFR (estimated glomerular filtration rate) 20-59 mL/min (milliliters per minute) * albuminuria \<300 mg/g (milligrams per gram) Exclusion Criteria: * Type 1 or 2 diabetes mellitus * expected to start dialysis or receive kidney transplantation or die within 4 months * prior therapy with SGLT2i (Sodium-Glucose Co-Transporter 2 inhibitors) within the previous year * unable to participate in the physical function tests (hand grip, walk) * infections requiring intravenous antibiotic treatment * malignancy requiring systemic therapy * extremity skin ulceration requiring active therapy * history of Fournier's gangrene * severe hypoglycemia requiring external assistance within the past one year * known allergy to empagliflozin * pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-diabetic chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-diabetic chronic kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah, 84148-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.